Metabolon has secured $13.1 million in a Series D financing. New investor Keating Capital, joins existing investors including Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners in the round.
"We are pleased by the participation of current investors in the Series D round, and are delighted to have esteemed new investor Keating Capital among our backers. We have recorded a 45% revenue CAGR since 2007, and expect 2011 revenues to be approximately $20 million. The proceeds of this financing will support further growth in our Metabolytics division and ongoing development of our oncology diagnostics product portfolio,” said John Ryals, president and chief executive officer of Metabolon.